Zhengye Biotechnology Holding Limited Regains Compliance with Nasdaq Bid Price Requirement
Rhea-AI Summary
Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) announced that Nasdaq has confirmed the company regained compliance with the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2). Nasdaq determined that, from July 20, 2026 to August 4, 2026, Zhengye’s Class A ordinary shares closed at or above $1.00 for 10 consecutive business days.
The prior May 29, 2026 Nasdaq notice had followed 30 consecutive business days with a bid price below $1.00. Zhengye’s shares continue to be listed on the Nasdaq Capital Market under the ticker “ZYBT”. The company also highlights its long-standing veterinary vaccine operations in China and selected overseas markets.
Positive
- Regains Nasdaq bid-price compliance after 10 consecutive days ≥ $1.00 (July 20–August 4, 2026)
- Nasdaq Capital Market listing maintained under ticker ZYBT
- Established product portfolio of 50 veterinary vaccines sold across 29 provincial regions in China and exported to Vietnam, Pakistan, and Egypt
Negative
- Prior bid-price deficiency triggered by 30 consecutive business days below $1.00 per share as of May 29, 2026
Market reaction after Nasdaq compliance update: ZYBT -20.97%
Following this news, ZYBT has declined 20.97%, reflecting a significant negative market reaction. Argus tracked a peak move of +6.6% during the session. Our momentum scanner has triggered 26 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $1.86.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 21 | Unusual trading statement | Neutral | -64.4% | Company denied material non-public information while responding to unusual trading activity. |
| Jun 04 | Bid price deficiency | Negative | +0.1% | Nasdaq notified company of minimum bid price deficiency after 30 business days. |
| Apr 28 | Fiscal 2025 results | Negative | -5.7% | Fiscal 2025 revenue declined and company reported a net loss. |
| Apr 06 | Dual-class structure | Neutral | +1.2% | Shareholders approved dual-class structure with differentiated voting rights. |
| Feb 10 | Chairman shareholder letter | Positive | -2.9% | Chairman’s letter highlighted patents, approvals, funding, and international registration progress. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historical news reactions were predominantly divergent, with four of five selected events moving opposite to or remaining inconsistent with the announcement direction.
Key Terms
minimum bid price requirement regulatory
closing bid price financial
good manufacturing practices for veterinary drugs regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Jilin, China, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced that on August 5, 2026, the Company received a letter (the “Compliance Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement of
As previously disclosed, on May 29, 2026, the Company received a notification letter from Nasdaq indicating that the closing bid price of the Company’s Class A ordinary shares had been below
Zhengye continues to be listed on The Nasdaq Capital Market under the ticker symbol “ZYBT”.
About Zhengye Biotechnology Holding Limited
Through Jilin Zhengye Biological Products Co., Ltd., the Company’s operating entity based in Jilin, China, Zhengye Biotechnology Holding Limited focuses on the research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. For over 20 years, the operating entity has been committed to enhancing the health of animals. The operating entity has 50 veterinary vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The operating entity’s products are available in 29 provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt as of the date of this press release. The operating entity has three veterinary vaccine production floors (including 13 vaccine production lines), one quality examination center, and one animal facility for vaccine development, all operating in accordance with Good Manufacturing Practices for Veterinary Drugs issued by the Ministry of Agriculture and Rural Affairs of the PRC. For more information, please visit the Company’s website: http://ir.jlzybio.com.
Forward-Looking Statements
This announcement contains statements that may constitute “forward-looking” statements which are made pursuant to the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions in this announcement. Statements that are not historical facts, including statements about the Company’s beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the United States Securities and Exchange Commission.
For more information, please contact:
Zhengye Biotechnology Holding Limited
Investor Relations Department
Email: ir@jlzybio.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
